Cancer Cytopathology最新文献

{"title":"Growing cancer risks on a warming planet","authors":"Bryn Nelson PhD, William Faquin MD, PhD","doi":"10.1002/cncy.22819","DOIUrl":"https://doi.org/10.1002/cncy.22819","url":null,"abstract":"<p>In August 2017, unusually warm waters in the western Gulf of Mexico helped a sputtering tropical storm to re-form into what would become the most damaging hurricane in recorded Texas history. Hurricane Harvey dumped a record 52 inches of rain into Houston’s Cedar Bayou and flooded the heavily industrialized Houston Ship Canal along with the petrochemical facilities lining its banks and at least 13 Superfund sites.</p><p>When the floodwaters receded, the tons of chemical contaminants left behind brought a worrisome new trend into sharp relief: Climate change may be significantly increasing some communities’ exposure to carcinogens. That exposure is being felt most heavily by communities already bearing the brunt of health inequities, compounding the danger. After climate scientists calculated that nearly 30% of Harvey’s rainfall could be attributed to global warming, a 2022 study estimated that climate change was responsible for up to half of all flooded properties in Harris County, which includes Houston.<span><sup>1</sup></span> Low-income Latino neighborhoods, such as the ones near the ship canal, were hit the hardest.</p><p>Leticia Nogueira, PhD, MPH, scientific director of health services research at the American Cancer Society, says that the hurricane triggered an epiphany of how the same extracting processes that release greenhouse gases into the atmosphere—the burning of fossil fuels—are also releasing carcinogens into surrounding communities. “I had to witness a very acute, very extreme exposure to make the connection in my brain, but this is happening in many communities in a longer-term, lower dose all the time,” she says. “We’re just not thinking about it.”</p><p>Increasingly extreme events—hurricanes, floods, wildfires, heat waves, and droughts among them—are helping Dr Nogueira and other researchers to connect the dots between climate change and higher cancer risks and worse outcomes for patients diagnosed with malignancies. The individual and synergistic effects of climate change and natural disasters fueled by global warming, they warn, are threatening to undo decades of progress in cancer prevention, detection, and treatment. The growing threat, however, may create a new opening to shine a light on the widening health disparities in vulnerable communities as well as the global consequences of doing nothing to address a warming planet.</p><p>Parsing the environmental contributors to diseases with multifactorial causes such as skin cancer can be tricky, says Eva Rawlings Parker, MD, assistant professor of dermatology at Vanderbilt University Medical Center in Nashville, Tennessee. Even so, she concluded in a review of available data that “strong circumstantial evidence supports the hypothesis that factors related to climate change, including stratospheric ozone depletion, global warming, and ambient air pollution, have likely contributed” to the growing global incidence of skin cancer.<span><sup>2</sup></span></p><p>Higher temper","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 4","pages":"200-201"},"PeriodicalIF":3.4,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22819","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140533838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular analysis using SalvGlandDx improves risk of malignancy estimation and diagnosis of salivary gland cytopathology: An exploratory multicenter study","authors":"Sandra N. Freiberger PhD,&nbsp;Kristian Ikenberg MD,&nbsp;Demi van Egmond,&nbsp;Sofie Claerhout PhD,&nbsp;Tom van Wezel PhD,&nbsp;Isabelle Vanden Bempt PharmD, PhD,&nbsp;Jeroen N. van Rossem MSc,&nbsp;Simon A. Mueller MD,&nbsp;Paul M Clement MD PhD,&nbsp;Vincent Vander Poorten MD PhD MSc,&nbsp;Danielle Cohen MD PhD,&nbsp;Esther Hauben MD,&nbsp;Niels J. Rupp MD","doi":"10.1002/cncy.22814","DOIUrl":"10.1002/cncy.22814","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Diagnosis of salivary gland neoplasms is challenging, especially on cytological specimens acquired by fine-needle aspiration. The recently implemented standardized Milan system for reporting salivary gland cytopathology provides an estimated risk of malignancy (ROM); yet, for two of the categories, the diagnosis of the lesion remains unclear. However, a precise diagnosis is desirable for optimal patient management, including planning of surgery and imaging procedures.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Cytological specimens (<i>n</i> = 106) were subjected to molecular analysis using the SalvGlandDx panel. The risk of malignancy was calculated for each detected alteration based on the diagnosis of the resection specimen. By taking into account the molecular alterations, their associated ROM, the clinical and cytological features, and the current literature, the Milan category was evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of <i>n</i> = 63 technically valid cases, 76% revealed a molecular alteration. A total of 94% of these molecularly altered cases could be assigned to a different Milan category when additionally taking molecular results into account. In only 2% of the salivary gland neoplasms of uncertain malignant potential, in which a molecular alteration was detected, the classification remained salivary gland neoplasms of uncertain malignant potential.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Molecular analysis of cytological specimens provides a benefit in classifying salivary gland neoplasms on fine-needle aspiration. It can improve the ROM estimation and thus help to assign cases of formerly unknown malignant potential to clearly benign or malignant categories.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 7","pages":"435-446"},"PeriodicalIF":2.6,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22814","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140334787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Papillae, psammoma bodies, and/or many nuclear pseudoinclusions are helpful criteria but should not be required for a definitive cytologic diagnosis of papillary thyroid carcinoma: An institutional experience of 207 cases with surgical follow up","authors":"Tarik M. Elsheikh MD,&nbsp;Matthew Thomas MD,&nbsp;Jennifer Brainard MD,&nbsp;Jessica Di Marco CT(ASCP),&nbsp;Erica Manosky CT(ASCP),&nbsp;Bridgette Springer CT(ASCP),&nbsp;Dawn Underwood MS CT(ASCP),&nbsp;Deborah J. Chute MD","doi":"10.1002/cncy.22817","DOIUrl":"10.1002/cncy.22817","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Noninvasive follicular thyroid neoplasm with papillary-like features (NIFTP) was introduced in 2016 replacing noninvasive follicular variant of papillary thyroid carcinoma, with recommendations to label them “noncancer.” To avoid reducing risk of malignancy (ROM) and overdiagnosing NIFTP as malignant, some authors required restricted cytologic criteria (RC) for a definitive diagnosis of papillary thyroid carcinoma (PTC), including papillae, psammoma bodies. or ≥3 nuclear pseudoinclusions. Since then, NIFTP criteria have been revised, biologic behavior better understood, and incidence reported to be much lower than initially anticipated. This study examines the impact of RC on PTC cytologic diagnoses, ROM, and detection of clinically significant carcinomas (CSC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>A total of 207 thyroid FNAs originally diagnosed as PTC and suspicious for PTC (SPTC) with surgical follow-up were evaluated. RC were retrospectively applied to cases as a requirement for diagnosing PTC, and cases that did not meet RC were reclassified as SPTC. ROMs and diagnostic accuracies of pre- and post-RC diagnoses were correlated with followup CSC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>RC were met in 118/142 (83%) and 20/65 (31%) of cases originally diagnosed as PTC and SPTC, respectively. Post-RC, 29% (19/65) of CSC originally diagnosed as SPTC were upgraded to PTC, and 17% (24/142) of CSC originally diagnosed as PTC were downgraded to SPTC. No NIFTPs were diagnosed as malignant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>RC should not be required for a definitive diagnosis of PTC when other nuclear features of PTC are diffuse and overt. Applying RC, however, helps the pathologist arrive at a more definitive diagnosis of PTC in suspicious cases.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 6","pages":"348-358"},"PeriodicalIF":3.4,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22817","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140334788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid nodules with DICER1 mutation or PTEN alteration: A comparative cytologic, clinical, and molecular study of 117 FNA cases","authors":"Tikamporn Jitpasutham MD,&nbsp;Stefen Andrianus MD,&nbsp;Maria Gubbiotti MD, PhD,&nbsp;Vania Nosé MD, PhD,&nbsp;Zubair W. Baloch MD, PhD,&nbsp;Emilio Madrigal MD,&nbsp;William C. Faquin MD, PhD","doi":"10.1002/cncy.22811","DOIUrl":"10.1002/cncy.22811","url":null,"abstract":"<p>Although <i>DICER1</i> patients are younger, and PTEN patients have more multinodular disease, <i>DICER1</i> and PTEN FNAs reveal many cytologic similarities. Awareness of these genetic cohorts can identify patients at risk for thyroid cancer.</p>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 6","pages":"370-385"},"PeriodicalIF":3.4,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140334789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risks of malignancy in the major nongynecologic cytopathology reporting systems: Critiques and discussions","authors":"Marc P. Pusztaszeri MD, PhD,&nbsp;Mauro Saieg MD, PhD,&nbsp;Zubair W. Baloch MD, PhD","doi":"10.1002/cncy.22809","DOIUrl":"10.1002/cncy.22809","url":null,"abstract":"<p>The ever-increasing popularity of standardized systems for reporting cytopathology has led in part to much attention to and importance of the risk stratification schemes, especially the risks of malignancy (ROMs), which are associated with the different diagnostic categories and upon which recommendations for clinical management are based. However, it is well known that the ROM calculations are based on retrospective reviews of the existing literature, representing a heterogeneous patient population, and are plagued by significant biases and variations. Statistically, the ROM represents the post-test probability of malignancy, which changes with the test result and with the prevalence of malignancy (or pretest probability) in an individual practice setting and individual patient presentation. Therefore, the clinical utility of the ROM is questioned and likely needs a second look in the nongynecologic cytopathology reporting systems. In this communication, the authors discuss the status of the ROM estimates according to the most commonly used nongynecologic reporting systems, including for thyroid, salivary glands, and others, highlighting similarities and differences with a focus on the limitations of ROM estimates and their application in clinical practice.</p>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 8","pages":"467-480"},"PeriodicalIF":2.6,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22809","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140325041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The updated College of American Pathologists principles of analytic validation of immunohistochemical assays: A step forward for cytopathology","authors":"Sinchita Roy-Chowdhuri MD, PhD","doi":"10.1002/cncy.22818","DOIUrl":"10.1002/cncy.22818","url":null,"abstract":"","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 9","pages":"547-548"},"PeriodicalIF":2.6,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140292969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive evaluation of cytomorphologic, histologic, and molecular features of DICER1-altered thyroid lesions on FNA: A multipractice experience","authors":"Krisztina Lengyel MD,&nbsp;Daniel J. Lubin MD,&nbsp;Wen-Yu Hsiao MD,&nbsp;Sam Sirotnikov DO,&nbsp;Guangju Luo MD,&nbsp;James W. Roberts MD,&nbsp;Qiuying Shi MD MS,&nbsp;Kelly Magliocca DMD,&nbsp;Melinda M. Lewis MD,&nbsp;Donald L. Sears MD,&nbsp;Ghulam Ilyas MD,&nbsp;Beverly B. Rogers MD,&nbsp;Kartik Viswanathan MD PhD","doi":"10.1002/cncy.22805","DOIUrl":"10.1002/cncy.22805","url":null,"abstract":"<p>A comprehensive multipractice cytologic-histologic-molecular correlation of a <i>DICER1</i>-altered thyroid lesion cohort, comprising one of the largest to date.</p>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 6","pages":"359-369"},"PeriodicalIF":3.4,"publicationDate":"2024-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140193456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incorporation of DNA methylation profiling into the cytopathology laboratory","authors":"Gloria H. Sura MD,&nbsp;Leomar Y. Ballester MD, PhD","doi":"10.1002/cncy.22810","DOIUrl":"10.1002/cncy.22810","url":null,"abstract":"","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 9","pages":"543-546"},"PeriodicalIF":2.6,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140130724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growing threats of a mass exodus in governmental public health","authors":"Bryn Nelson PhD,&nbsp;William Faquin MD, PhD","doi":"10.1002/cncy.22804","DOIUrl":"10.1002/cncy.22804","url":null,"abstract":"&lt;p&gt;The backbone of the nation’s public health workforce is buckling.&lt;/p&gt;&lt;p&gt;A recent study has raised alarms with its dire prediction of a mass exodus of governmental public health workers—considered the “backbone” of public health efforts in the United States—if current trends hold.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; “In our analytic sample, nearly half of all employees in state and local public health agencies left between 2017 and 2021, a proportion that rose to three-quarters for those ages 35 and younger or with shorter tenures,” the study’s authors wrote. “If separation trends continue, by 2025 this would represent more than 100,000 staff leaving their organizations, or as much as half of the governmental public health workforce in total.”&lt;/p&gt;&lt;p&gt;Based on data from the Public Health Workforce Interests and Needs Surveys in 2017 and 2021, the study has raised troubling questions about the country’s health priorities and the ability of local and state governments to recruit and retain new talent to help fill a yawning gap. “If you saw half or three quarters of firefighters or police indicating that they were planning to quit, much less retire, I think that would be pretty concerning. That’s kind of where we are right now in public health,” says lead author Jonathon Leider, PhD, an associate professor of public health and the director of the Center for Public Health Systems at the University of Minnesota in Minneapolis.&lt;/p&gt;&lt;p&gt;Many of the public health jobs lost during the Great Recession of 2008–2009 never returned and left governments with a workforce deficit, Dr Leider says. Then, older employees who had delayed retirement during the recession started to leave during the economic recovery. Their departure was compounded by what some demographers have dubbed the “silver tsunami,” or the wave of baby boomers reaching retirement age.&lt;/p&gt;&lt;p&gt;“We’ve been investing in this short-age for a long time,” adds study coauthor Brian Castrucci, DrPH, MA, president and chief executive officer of the de Beaumont Foundation in Bethesda, Maryland, which focuses on improving community health and public health systems. By the start of the COVID-19 pandemic, he notes, a lack of attention to filling the available positions and increasing low pay rates had already contributed to a shortage of 80,000 full-time equivalents.&lt;/p&gt;&lt;p&gt;The pandemic then led to “unprecedented levels of bullying, politicization, and political attacks on the public health workforce,” he charges. Amid that hostile environment, employees were pulled from other health department divisions to bolster short-staffed pandemic response teams, which added to the stress. “This is just a recipe for burnout,” he says. “The pandemic was an accelerant, but the fire was already burning.”&lt;/p&gt;&lt;p&gt;Emily Burke, EdD, MPH, senior director of workforce development and applied practice at the Association of Schools and Programs of Public Health in Washington, DC, says that a continuation of the alarming exodus could have major ","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 3","pages":"134-135"},"PeriodicalIF":3.4,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22804","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140048806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving diagnostic yield of pancreatic serous cystadenoma with cyst fluid ancillary testing, adjunct immunohistochemistry, and additional fine-needle biopsy sampling","authors":"Xi Wang MD, PhD,&nbsp;Xuchen Zhang MD, PhD,&nbsp;Pei Hui MD, PhD,&nbsp;Guoping Cai MD","doi":"10.1002/cncy.22808","DOIUrl":"10.1002/cncy.22808","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Fine-needle aspiration (FNA) diagnosis of pancreatic serous cystadenoma (SCA) remains challenging. This retrospective study aimed to evaluate the roles of cyst fluid ancillary testing and combined fine-needle biopsy (FNB) in improving the diagnostic yield.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The authors retrospectively reviewed cytology cases that were histologically confirmed SCAs. Clinical features and FNA cyst fluid biochemical and molecular analysis results along FNB findings were reviewed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study cohort included 31 cases from 13 male and 18 female patients with a mean age of 65. The original cytologic diagnoses were nondiagnostic (<i>n</i> = 6, 19%), negative for malignant cells/cyst contents (<i>n</i> = 7, 23%), atypical cells (<i>n</i> = 3, 10%), nonmucinous cyst (<i>n</i> = 11, 35%), and serous cystadenoma (<i>n</i> = 4, 13%). Cyst fluid carcinoembryonic antigen (CEA) analysis was performed in 17 cases, all of which showed a low CEA level (&lt;192 ng/mL). All 14 cases with molecular testing showed a wild-type <i>KRAS</i>. Inhibin immunohistochemistry was retrospectively performed on the FNA cell blocks, inhibin was positive in six of seven cases tested. In 15 cases with concurrent FNA and FNB biopsies, the diagnosis of SCA was seen in only one FNA case (7%) but 13 FNB cases (87%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study suggests that FNA diagnosis of SCA remains challenging even with ancillary testing including cyst fluid CEA level and <i>KRAS</i> mutation analysis. Adjunct inhibin immunostaining may help improve the cytologic diagnosis of selective SCA cases. FNB appears superior to FNA for a definite diagnosis of SCA.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 7","pages":"425-434"},"PeriodicalIF":2.6,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140048852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}